Safinamide (Xadago) is a selective monoamine oxidase type B (MAO-B) inhibitor. Used as an adjunctive therapeutic agent to levodopa/carbidopa, it is indicated for improving "off" period symptoms in patients with Parkinson's disease (PD).

How Effective is Safinamide (Xadago) in Treatment?

Core Therapeutic Effects

Improvement of motor symptoms: As an adjunct to levodopa, it can significantly reduce the "off" period duration in Parkinson's disease patients, prolong the "on" period duration without exacerbating dyskinesia.

Dual mechanisms of action: It reduces dopamine degradation by inhibiting MAO-B, and at the same time modulates glutamatergic neurotransmission, thereby enhancing the therapeutic efficacy of levodopa.

Clinical Advantages and Limitations

Advantages:

Compared with dopamine receptor agonists, safinamide does not increase the risk of impulse control disorders.

Compared with other MAO-B inhibitors, it does not require strict tyramine-restricted diets (at conventional doses).

Limitations: It can only be used as an adjunctive therapy and is ineffective for the monotherapy of Parkinson's disease.

Suitable Population for Safinamide (Xadago)

Target Patient Population

Clear indication: Adult patients diagnosed with Parkinson's disease who are already receiving levodopa/carbidopa treatment but still experience "off" periods.

Contraindicated Population

Contraindications due to drug interactions: Concomitant use with MAO inhibitors (e.g., linezolid), opioid drugs (e.g., tramadol), tricyclic antidepressants, St. John's wort, etc., is prohibited.

Other contraindications: Patients with a history of hypersensitivity to safinamide or severe hepatic impairment (Child-Pugh Class C).

Medication Monitoring for Safinamide (Xadago)

Pre-Treatment Assessment

Baseline examinations: Liver function (ALT/AST), blood pressure, electrocardiogram (QT interval), and mental status assessment.

Medication history screening: Strictly screen for contraindicated concomitant medications (e.g., SSRIs, SNRIs, dextromethorphan).

Intra-Treatment Monitoring

Blood pressure management: Regularly monitor blood pressure, especially in patients with comorbid hypertension or those receiving concomitant vasopressor medications (e.g., decongestants).

Observation of psychiatric symptoms: Pay attention to adverse reactions such as hallucinations and impulsive behaviors (e.g., pathological gambling, binge eating).

Liver function and visual acuity: Patients with moderate hepatic impairment need regular rechecks of liver function; patients with a history of retinopathy should be monitored for changes in visual acuity.

Monitoring for Severe Reactions

Hypertensive crisis: Discontinue the drug immediately and initiate antihypertensive treatment.

Serotonin syndrome: Discontinue all sensitizing drugs and provide supportive treatment.

Excessive daytime sleepiness: Advise patients to avoid driving or operating machinery; adjust the dosage if necessary.